GlassScriptPhysician profile
Clyde Watkins
NPI 1851311856
$9,079.96
in general payments reported to CMS, 2019-2025
22 companies · $3,965 in 2025
The $3,965 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $811 · 2021: $391 · 2022: $215 · 2023: $590 · 2024: $2,456 · 2025: $3,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $1,517 · Travel and Lodging: $993 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $1,517.02 |
| Travel and Lodging | $993.14 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $5,846.15 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $853.07 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $472.23 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $290.39 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $254.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.02 | 2020-2024 | Jardiance |
| Glaxosmithkline, LLC. | $136.45 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $116.08 | 2020-2024 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $113.50 | 2019-2021 | |
| Abbvie INC. | $109.29 | 2023-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $108.59 | 2024 | |
| Sanofi-Aventis U.S. LLC | $108.35 | 2019-2020 | |
| Amgen INC. | $97.78 | 2020-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.34 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $79.11 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.17 | 2019-2022 | |
| Astellas Pharma US INC | $48.91 | 2023-2024 | Veozah |
| Pfizer INC. | $42.50 | 2019-2024 | |
| Boston Scientific Corporation | $23.72 | 2021 | |
| Dexcom, INC. | $23.08 | 2023 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $21.48 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.